Prevalence of Antidepressant Use During Pregnancy in Denmark, a Nation-wide Cohort Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 3

PMID 23638179

Citations 49

Authors

Espen Jimenez-Solem

Jon Traerup Andersen

Morten Petersen

Kasper Broedbaek

Nadia Lyhne Andersen

Christian Torp-Pedersen

Henrik Enghusen Poulsen

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of this study was to assess the prevalence and patterns of exposure to antidepressants before, during and after pregnancy in a cohort including all pregnant women in Denmark between 1997 and 2010.

Methods: We performed a retrospective cohort study including 912 322 pregnancies. Information was retrieved from the Danish Birth Registry and The Register of Medicinal Product Statistics to identify women redeeming an antidepressant prescription during pregnancy. Exposure periods were based on standard treatment doses and dispensed pack sizes.

Results: We identified 19 740 pregnancies exposed to an antidepressant at some point during pregnancy. The rate of exposure increased from 0.2% in 1997 to 3.2% in 2010. We found that the rate of exposure was halved during the first 3 months of pregnancy. In contrast, we describe a clear increase in exposure after pregnancy among pre-delivery treatment-naïve women.

Conclusions: In spite of uncertainty concerning antidepressants' safety during pregnancy we find a 16-fold increase in exposure rates between 1997 and 2010. The rates describe a sharp decrease in exposure during pregnancy that is probably caused by physicians' hesitation to prescribe antidepressants and women's fear of unwanted effects on the unborn child. More studies are needed to clarify the consequences of antidepressant discontinuation during pregnancy.

Citing Articles

Citalopram exposure of hESCs during neuronal differentiation identifies dysregulated genes involved in neurodevelopment and depression.

Spildrejorde M, Leithaug M, Samara A, Aass H, Sharma A, Acharya G Front Cell Dev Biol. 2024; 12:1428538.

PMID: 39055655 PMC: 11269147. DOI: 10.3389/fcell.2024.1428538.

Sex-Specific Transcriptomic Changes in the Villous Tissue of Placentas of Pregnant Women Using a Selective Serotonin Reuptake Inhibitor.

Staal L, Plosch T, Kallak T, Poromaa I, Wertheim B, Olivier J ACS Chem Neurosci. 2024; 15(6):1074-1083.

PMID: 38421943 PMC: 10958514. DOI: 10.1021/acschemneuro.3c00621.

Prevalence of Selective Serotonin Reuptake Inhibitor Use Among Pregnant Women From 2017 to 2020 in King Abdulaziz Medical City, Jeddah, Saudi Arabia: A Retrospective Study.

Hakami A, Ahmad R, Bukhari M, Almalki M, Ahmed M, Alghamdi M Cureus. 2023; 15(10):e47745.

PMID: 38021702 PMC: 10676232. DOI: 10.7759/cureus.47745.

Psychiatric disorders during pregnancy in asymptomatic and mildly symptomatic SARS-CoV-2 positive women: Prevalence and effect on outcome.

Abulseoud O, Chan B, Rivera-Chiauzzi E, Egol C, Nettey V, Van Ligten M Psychiatry Res. 2023; 326:115313.

PMID: 37336168 PMC: 10273774. DOI: 10.1016/j.psychres.2023.115313.

Prenatal antidepressant exposure and emotional disorders until age 22: a danish register study.

Bliddal M, Wesselhoeft R, Strandberg-Larsen K, Ernst M, Weissman M, Gingrich J Child Adolesc Psychiatry Ment Health. 2023; 17(1):73.

PMID: 37328889 PMC: 10276495. DOI: 10.1186/s13034-023-00624-9.

References

Kallen B, Olausson P . Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007; 79(4):301-8. DOI: 10.1002/bdra.20327. View

Andersen T, Madsen M, Jorgensen J, Mellemkjoer L, Olsen J . The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999; 46(3):263-8. View

Bennett H, Einarson A, Taddio A, Koren G, Einarson T . Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004; 103(4):698-709. DOI: 10.1097/01.AOG.0000116689.75396.5f. View

Davis R, Rubanowice D, McPhillips H, Raebel M, Andrade S, Smith D . Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007; 16(10):1086-94. DOI: 10.1002/pds.1462. View

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M . Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012; 344:d8012. DOI: 10.1136/bmj.d8012. View

Kulin N, Pastuszak A, Sage S, Spivey G, Feldkamp M, Ormond K . Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998; 279(8):609-10. DOI: 10.1001/jama.279.8.609. View

Cohen L, Altshuler L, Harlow B, Nonacs R, Newport D, Viguera A . Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006; 295(5):499-507. DOI: 10.1001/jama.295.5.499. View

Schatzberg A . New indications for antidepressants. J Clin Psychiatry. 2000; 61 Suppl 11:9-17. View

Simon G, Cunningham M, Davis R . Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002; 159(12):2055-61. DOI: 10.1176/appi.ajp.159.12.2055. View

10.

Tilley B, Barnes A, Bergstralh E, Labarthe D, Noller K, Colton T . A comparison of pregnancy history recall and medical records. Implications for retrospective studies. Am J Epidemiol. 1985; 121(2):269-81. DOI: 10.1093/oxfordjournals.aje.a113997. View

11.

de Jong van den Berg L, Feenstra N, Sorensen H, Cornel M . Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology. 1999; 60(1):33-6. DOI: 10.1002/(SICI)1096-9926(199907)60:1<33::AID-TERA9>3.0.CO;2-X. View

12.

Petersen I, Gilbert R, Evans S, Man S, Nazareth I . Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry. 2011; 72(7):979-85. DOI: 10.4088/JCP.10m06090blu. View

13.

Lennestal R, Kallen B . Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007; 27(6):607-13. DOI: 10.1097/jcp.0b013e31815ac4d2. View

14.

Chatillon O, Even C . [Antepartum depression: prevalence, diagnosis and treatment]. Encephale. 2010; 36(6):443-51. DOI: 10.1016/j.encep.2010.02.004. View

15.

Sorensen H, Hansen I, Ejlersen E, Sabroe S, Hamburger H . Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. J Med Syst. 1996; 20(1):57-65. DOI: 10.1007/BF02260874. View

16.

OBrien L, Laporte A, Koren G . Estimating the economic costs of antidepressant discontinuation during pregnancy. Can J Psychiatry. 2009; 54(6):399-408. DOI: 10.1177/070674370905400607. View

17.

Ericson A, Kallen B, Wiholm B . Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999; 55(7):503-8. DOI: 10.1007/s002280050664. View

18.

Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E . Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008; 66(5):695-705. PMC: 2661986. DOI: 10.1111/j.1365-2125.2008.03261.x. View

19.

Chung T, Lau T, Yip A, Chiu H, Lee D . Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 2001; 63(5):830-4. DOI: 10.1097/00006842-200109000-00017. View

20.

Malm H, Artama M, Gissler M, Ritvanen A . Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011; 118(1):111-120. DOI: 10.1097/AOG.0b013e318220edcc. View